<DOC>
	<DOCNO>NCT00154232</DOCNO>
	<brief_summary>The aim study ass short-term benefit combination basiliximab , EC-MPS cyclosporine microemulsion C2 monitoring prophylaxis acute rejection population de novo renal transplant patient potential high risk DGF .</brief_summary>
	<brief_title>Study Evaluate Combination Enteric-coated Mycophenolate Sodium ( EC-MPS ) , Basiliximab , C2-monitored Cyclosporine de Novo Renal Transplant Recipients Potential High Risk Delayed Graft Function ( DGF )</brief_title>
	<detailed_description />
	<mesh_term>Delayed Graft Function</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Age 1870 year old Patients receive primary secondary cadaveric live donor kidney Patients give write informed consent study participation Females capable become pregnant must negative pregnancy test baseline require practice birth control duration study least four month follow last dose basiliximab . Recipient multiorgan transplant previously transplant organ kidney Recipient dual kidney transplant Recipient transplant kidney NonHeart Beating Donor ( NHBD ) Recipient HLA identical livingdonor kidney Patients PRA level ( past current level ) great 20 % Patients anticipated investigator require induction therapy OKT3 , ATGAM , Thymoglobulin reason Patients medical condition , opinion investigator , would preclude patient participate study Cold ischemia time large 36 hour . Patients receive investigational drug therapy within one month prior study entry therapy institute posttransplantation . Female transplant candidate pregnant , lactating , childbearing potential willing practice acceptable method contraception Patients know hypersensitivity cyclosporine Patients known malignancy history malignancy , successfully treat nonmetastatic basal squamous cell carcinoma skin Known HIV positive antibody status Evidence clinically relevant ( per investigator determination ) active infection Patients unable participate study full 3month study period Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Renal transplantation , DGF , basiliximab , EC-MPS , cyclosporine</keyword>
</DOC>